aTyr Pharma initiates Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD

aTYR PHARMA INC

EFZO-CONNECT is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study in systemic sclerosis-associated ILD.
Study enrolls 25 patients across multiple US centers; 28-week treatment with monthly IV doses of efzofitimod (270 mg or 450 mg) or placebo.
Primary objective: evaluate efficacy of efzofitimod on pulmonary, cutaneous, and systemic manifestations in SSc-ILD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.